The use of venetoclax in the treatment of acute lymphoblastic leukemia-a systematic review.

ABSTRACT:

Background

The 5-year overall survival rates in acute lymphoblastic leukemia (ALL) vary depending on the patient's age group (from 93% to under 30%). However, in the case of relapsed/refractory ALL (R/R ALL), the complete remission (CR) rate in the pediatric patient group is 44% and in the adult population-18%. Therefore, further research on new therapeutic compounds is necessary.

Objectives

This systematic review aims to analyze the results of clinical studies concerning the use of venetoclax alone or in combination with other drugs in the treatment of ALL.

Design

The systematic review was conducted in accordance with the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis. The Quality Assessment Tool for Before-After (Pre-Post) Studies W

SUBMITTER: Kowalczyk A 

PROVIDER: S-EPMC12783563 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature